TIME MAGAZINE  by Alexandra Sifferlin                                             March 25, 2015
An efficacy trial for an Ebola vaccine launched in Guinea on Wednesday.

 A health worker prepares a vaccination on March 10, 2015 at a health center in Conakry during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus.

The vaccine, VSV-EBOV, was developed by the Public Health Agency of Canada and has already shown positive results in smaller safety trials. NewLink Genetics and Merck are collaborating on the vaccine, and the Guinean government and World Health Organization (WHO) are leading the trial, which is taking place in Basse-Guinée, a community where many Ebola cases spread.

A new study shows the durability of a novel 'disseminating' cytomegalovirus (CMV)-based Ebola virus (Zaire ebolavirus; EBOV) vaccine strategy that may eventually have the potential to reduce ebolavirus infection in wild African ape species.

These are western lowland gorillas, one of the great ape species threatened by Ebola. Credit: Copyright 2012 Chris Whittier

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

The multi-institutional study is led by Dr Michael Jarvis at Plymouth University, and is published today, 25th March 2015, in Vaccine.

The BBC   by Hans Rosling                                                                    March 23, 2015
Interview with Swedish statistician and global health professor Hans Rosling who spent three months working as an epidemiologist in the Liberian Health Ministry helping to tackle the Ebola crisis.

                  Hans Rosling flanked by Maj Morris Hunh (China), to his right, and Gen Gary Volesky(U.S.) to his left

Excerpt from BBC interview:

The curve turned around because enough Ebola treatment units were built. Medecins Sans Frontieres ran the biggest. When that was not enough, Liberian doctors and nurses added the next treatment unit. But the race against time in September to provide treatment and isolation for all patients, when the epidemic curve climbed to 30, 40 and 50 patients per day, was won by the WHO.

 By the end of September, Dr Atai from Uganda opened the so-called Island Clinic which meant beds could be offered to all Ebola patients.The curve was curbed for four reasons: